🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Gyre Therapeutics, Inc. GYRE R2KPHARMA

Healthcare · Biotechnology · United States
https://www.gyretx.com
Company Profile ↓
$6.86
-16.44% 1Y
Mkt Cap$764.81M
P/E-85.75
P/B6.01
52W High$8.87
52W Low$5.56
Book Value$1.11
EPS (TTM)$-0.08

Company Overview

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 12.6% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $116.59M (+10.2% YoY); net profit $9.88M.
  • Trailing 12 Months Year-on-year growth — revenue +2.1%, earnings -44.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.55%
1 Year:2.10%

Compounded Profit Growth

5 Years:-
1 Year:-44.80%

Stock Price Performance

1 Year:-16.44%
6 Months:-11.02%
3 Months:+9.06%
1 Month:+7.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 39% of range
$5.56 $8.87
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)57.56 · Neutral
Price Performance
1M+7.19%
3M+9.06%
6M-11.02%
1Y-16.44%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-85.75
Industry PE
25.17
Forward P/E
114.33
PEG Ratio
-
Book Value
$1.11
Price to Book
6.01
P/S
6.35
EV/EBITDA
112.65
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
12.55%
Profit 5Y
-
Revenue (YoY)
2.10%
Earnings (YoY)
-44.80%

Profitability & Returns

ROCE
7.77%
ROE
-3.08%
ROA
1.03%
Profit Margin
-5.44%
Op Margin
-30.21%
Gross Margin
95.09%
EPS (Latest Qtr)
$-0.12
EPS (TTM)
$-0.08

Balance Sheet & Liquidity

Debt/Equity
0.60
Quick Ratio
3.68
Current Ratio
4.64
Debt
$823.00K
Total Assets
$199.25M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
74.40%
Chg in Prom Hold
-11.94%
FII / Inst Holding
8.20%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$764.81M
Total Revenue (TTM)
$117.05M
EBITDA
$5.07M
Free Cash Flow
$9.60M
Operating Cash Flow
$4.32M
Shares Outstanding
111.49M
Gross Margin
95.09%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GYRE Gyre Therapeutics, Inc. R2KPHARMA 6.86 -85.75 $764.81M 0.00% 7.77% -3.08% 12.55% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------111.00K318.00K6.00K-----16.37M1.66M893.00K1.47M1.13M2.30M794.00K--24.93M29.33M32.04M27.17M25.23M--22.06M26.77M30.56M37.20M22.52M29.11M
Cost of Revenue ----------------------------------894.00K1.15M1.63M1.74M1.23M-
Gross Profit ---------------------------23.81M28.25M30.86M26.19M24.45M--21.16M25.62M28.94M35.45M21.29M-
Operating Expenses ----------------------------------18.89M23.45M22.01M35.33M28.09M-
Operating Income -1.64M-1.80M-3.03M-2.20M-3.88M-4.68M-4.57M-4.92M-5.71M-4.17M-5.94M-5.88M-6.68M-7.11M-8.35M-15.71M-14.38M-13.20M-5.07M-17.36M-16.10M-22.44M-19.91M-25.23M-14.70M51.53M-5.17M6.66M4.97M12.76M8.07M3.19M--2.27M2.17M6.93M120.00K-6.80M-14.36M
EBITDA ----------------------------------2.81M2.81M7.58M815.00K-6.13M-
Interest Expense ----------------------------------------
Pretax Income ----------------------------------4.63M2.24M7.63M-66.00K-9.24M-
Tax Provision ----------------------------------901.00K662.00K1.69M1.30M621.00K-
Net Income -1.50M-1.30M-2.86M-1.72M-5.05M-5.13M-3.59M-4.83M-4.77M-4.14M-5.88M-5.79M-5.04M-6.48M-7.69M-15.08M-13.78M-12.71M-4.05M-17.25M-16.03M-22.44M-19.93M-25.24M-14.54M51.63M-4.88M4.22M3.77M7.51M9.94M4.54M--2.70M442.00K3.61M-1.72M-8.69M-14.27M
Diluted EPS -----------------------0.64-0.80-0.461.64-0.160.030.020.050.030.01--0.000.000.03-0.02-0.10-0.12
R&D Expense 1.34M-1.38M1.32M1.49M-2.29M2.75M3.40M2.06M3.40M3.81M3.77M3.89M5.58M12.03M11.11M9.93M13.26M12.91M12.25M17.01M15.39M20.35M9.70M1.87M803.00K2.63M3.57M3.01M2.18M3.35M2.77M-3.10M3.42M2.36M-6.74M-

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 25.06M85.71M97.64M57.86M3.63M275.00K--1.02M6.00K-20.95M7.34M102.29M113.45M105.76M116.59M
Gross Profit -------------97.50M108.81M101.87M-
Operating Income -40.33M13.12M-9.74M-8.14M-10.12M-7.51M-13.80M-20.42M-21.82M-33.82M-57.28M-57.37M-87.89M9.20M-67.23M16.16M11.49M
Net Income -39.40M10.90M-8.53M-7.00M-9.97M-6.61M-14.76M-16.95M-21.56M-30.05M-55.18M-56.24M-87.93M4.31M-85.48M17.90M9.88M
Diluted EPS -1.540.36-0.27-0.21---------2.870.03-1.410.050.02
R&D Expense 40.18M64.55M95.22M49.09M6.56M5.27M5.96M11.55M12.85M21.47M43.86M52.98M68.89M-13.78M12.02M13.70M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --262.79M258.13M189.58M145.87M2.98M69.52M38.09M39.51M124.92M98.55M94.85M55.66M84.75M116.54M125.41M166.13M
Total Equity 57.37M68.99M91.85M174.29M-93.34M-103.01M-109.35M31.43M16.07M30.77M119.94M68.34M76.07M41.09M42.52M-15.83M63.32M106.03M
Cash & Equivalents 51.20M83.91M165.85M107.28M3.40M2.83M1.54M29.10M10.26M14.47M31.21M15.37M30.36M44.35M25.18M33.51M11.81M37.07M
Long Term Debt --1.35M1.99M1.14M283.00K0-----------
Total Liabilities --170.94M83.84M13.66M11.26M3.46M38.10M22.02M8.74M4.97M30.22M18.78M14.57M12.54M38.06M27.00M23.85M
Current Liabilities --98.66M78.61M11.35M10.98M2.34M37.76M21.96M8.74M4.80M28.90M17.80M14.16M12.24M20.05M19.52M18.29M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -24.27M138.30M-83.72M-64.24M-40.61M----19.94M-28.55M-43.61M-55.05M-83.75M10.68M25.89M-3.64M1.01M
Investing Cash Flow 9.80M-62.80M-57.67M39.82M13.41M----11.20M-71.32M27.39M9.66M48.19M-13.81M-19.76M-19.88M-474.00K
Financing Cash Flow 47.18M6.45M82.81M-626.00K-552.00K---21.08M111.33M327.00K60.38M49.55M-45.01M2.50M2.10M24.38M
Capital Expenditure -200.00K-3.31M-1.43M-333.00K-41.00K-4.00K-272.00K-468.00K-23.00K-376.00K-64.00K--839.00K-4.99M-8.52M-2.31M-1.19M
Free Cash Flow -24.47M134.99M-85.15M-64.57M-40.65M----19.96M-28.93M-43.68M--84.59M5.69M17.38M-5.96M-180.00K
Share Buybacks ------82.00K----------
Dividends Paid -------------45.03M---

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------95.3%95.9%96.3%-
Operating Margin % -160.9%15.3%-10.0%-14.1%-278.9%-2,730.5%---2,143.6%-563,700.0%--273.9%-1,197.8%9.0%-59.3%15.3%9.9%
Net Margin % -157.2%12.7%-8.7%-12.1%-274.6%-2,404.7%---2,118.0%-500,916.7%--268.5%-1,198.3%4.2%-75.3%16.9%8.5%
ROE % -57.1%11.9%-4.9%7.5%9.7%6.0%-47.0%-105.4%-70.1%-25.1%-80.7%-73.9%-214.0%10.1%540.1%28.3%9.3%
ROCE % -8.0%-5.4%-4.6%-7.5%-1,164.2%-43.5%-126.6%-70.9%-28.2%-82.2%-74.5%-211.8%12.7%-69.7%15.3%7.8%

Shareholding Pattern

Insiders
74.40%
Institutions
8.20%
Public Float
32.01%

Top Institutional Holders

#Holder% HeldSharesValue
1 HSG Holding Ltd 3.36% 3.75M $24.71M
2 Blackrock Inc. 0.89% 993.94K $6.55M
3 Octagon Capital Advisors LP 0.86% 954.42K $6.29M
4 Vanguard Capital Management LLC 0.79% 876.93K $5.78M
5 Geode Capital Management, LLC 0.48% 532.95K $3.51M
6 State Street Corporation 0.22% 245.40K $1.62M
7 Charles Schwab Investment Management, Inc. 0.17% 184.29K $1.21M
8 SBI Securities Co., Ltd. 0.15% 166.75K $1.10M
9 Northern Trust Corporation 0.15% 169.54K $1.12M
10 Vanguard Fiduciary Trust Co 0.14% 151.07K $995.57K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GYRE

Google News hu, 03 Sep 2026

Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNTWZmUEYtY251TWJMNThQN2lTVzVMazdTQjBJSGR3VU5MREtibC05OENrYWkwRW5FNTR3RDJtcXRNNjI0NG0zTm9aaTNmbVdrRDhGdDBVUld1QlRQNElPQllScFRKR200YWNQZ3FUdVVQdFhjSklZbTNONExwZ1V6bE9KaU9SNDEwNzRZTn…

Google News Sat, 05 Sep 2026

Discipline and Rules-Based Execution in GYRE Response - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNUXlQVnlEVjZLbjIxMGVEQWN6RVhWYkFxOVVacmQtbXBXQkU5d3pmZy11Q1ptTHpWRWhMZGF5T1dXcERURk5XSm5WTWcxZlZ4YTBpZXhXWEkxR3RwTmNzRGZyN3lCd1Zxb3ZtNTNiM2dkWWtqbVFSUlpDTGpKbDh5YUF5SmdrUFNJb3E3d2…

Google News hu, 27 Aug 2026

Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPYXlwZmxGNFRZYXVlTk1HWUR1LW53dkFoWXcySEExY1JUelJfemRQYi1vcDVKeVpScV9mU0VoTWNUT0RTV0RjbmtyX3hONUk2aHFvZXZYVE9FNkY4WDhWUkgycE44cTQ4TDFvTEVDRTZKRk5XaEt0RTRfdW1ZX1l3VmhsVzd2ZmhqaEx3Zj…

Google News Fri, 07 Aug 2026

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOY1JSSjhhemhKM1JPVTRvSHlaaDRXTk81WjY5YzhraWoxQWN3dDl4YTdjSFNRRUdhSVFkaFBjRjZEUjVsb0N1TnBFWWF4MzlGRVRGNzVqV0FaZW92eklOVnNZMnRMVk1fbktiNVlneWk2MS1TWE9Fem91M2JoUHdSRHpDeG04V2ZJWkFMMz…

Google News hu, 03 Sep 2026

Gyre Therapeutics to Participate in Upcoming September Investor Conferences - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNR3pPVnBJTTRwLXdJbFgzUGtHTk5fZDZibUVkMEZNeS0tMVlid1kwREoxWGtiR2R0N000ODdZSGFOTXBiZHNwSnJRbThIU2lmM1V5azdSS29KVVhJa1RnY3RmN01zTHFGRDVjNWsxdmF6S3BCMENSSHJyU3lpNFQzeDJYRUFFdmt6RmUxQ1…

Google News Mon, 02 Mar 2026

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout - Fierce Biotech

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQbU1uRl81M1B0UEl4Q0JOcGVaekFZQjRkbFp3R1FYdy1HSm51WlppTWNRX1NyRVQtcXNZQzdTaWZRbHQzZm1OVnpOX3g3MHdodDlNdm9aOHNyQUlPWjZrTUQ1Z19DMWtheFd6QTdTT1hLeGQ3TlhMNTE2YVROaU82c3pzMk5aUUxONGw4eG…

GYRE — Frequently Asked Questions

What is the current share price of Gyre Therapeutics, Inc. (GYRE)?

As of 2026-09-07 16:24 PDT, Gyre Therapeutics, Inc. (GYRE) trades at $6.86 on NasdaqCM. Its 52-week range is $5.56 to $8.87.

What is the market capitalisation of GYRE?

Gyre Therapeutics, Inc. (GYRE) has a market capitalisation of $764.81M on NasdaqCM.

What is the P/E ratio of GYRE?

GYRE trades at a trailing price-to-earnings (P/E) ratio of -85.75. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.01.

What is the return on equity (ROE) of GYRE?

GYRE has a return on equity (ROE) of -3.08%. Its return on capital employed (ROCE) is 7.77%.

Is GYRE a good stock to buy?

This page provides a data-driven analysis of Gyre Therapeutics, Inc. (GYRE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space